<div class="p4l_caption"><div class="p4l_captionTitle"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2694616/" ref="ordinalpos=4228&amp;ncbi_uid=1936752&amp;link_uid=PMC2694616" image-link="/pmc/articles/PMC2694616/figure/F5/" class="imagepopup">Figure 5. Predicting clinical response with <span class="highlight" style="background-color:">pathway</span> module signatures.  From: A Genomic Strategy to Elucidate Modules of Oncogenic <span class="highlight" style="background-color:">Pathway</span> <span class="highlight" style="background-color:">Signaling</span> Networks. </a></div><br /><div class="p4l_captionBody">A. Cetuximab, a monoclonal antibody, targets the EGF receptor. Using a signature for EGFR activation as a starting point, we apply BFRM to decompose the pathway into 20 modules, as represented by gene expression signatures.B. Clinical response to cetuximab is assessed in 68 patients with advanced colorectal cancer (CRC), In these patients, we predict the activity of the 20 EGFR modules using the pathway module signatures. The plot shows that EGFR module 18 can significantly distinguish patients with response (R) and no response (NR) to the EGFR inhibitor cetuximab.C. Assessment of each of the EGFR, Ras, and E2F pathway module signatures for prediction of cetuximab response. The table shows the ability of each module to identify patients that respond to the EGFR inhibitor cetuximab. The p-value is calculated using a non-parametric Wilcoxon test that compares the predicted modules scores between responders and non-responders.</div></div>